Definium Therapeutics

About Definium Therapeutics

Definium Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. The company's lead product candidate, DT-200, is a first-in-class inhibitor of a key pathway implicated in tumor growth and metastasis. DT-200 has shown promising preclinical and early clinical results, demonstrating significant anti-tumor activity and a favorable safety profile. Definium Therapeutics is advancing DT-200 through Phase 1/2 clinical trials for various solid tumors. The company's pipeline also includes other promising drug candidates targeting different oncogenic pathways. Definium Therapeutics aims to address unmet medical needs in oncology by delivering innovative treatments to patients.